Key Points
- CIO Mitchell Young Williams sold 263,863 shares of Biosig (NASDAQ:STEX) at an average $0.79 for a total of $208,451.77 to cover tax withholding from vesting, reducing his stake by 7.99% to 3,037,648 shares.
- Shares of STEX fell about 14%, opening at $1.02 (50-day MA $1.49) with a 52‑week range of $0.70–$14.11 and a market cap near $183.9 million; the company reported a quarterly loss of $8.23 per share.
- Analyst sentiment is mixed but subdued: MarketBeat shows a consensus "Hold" rating and a $9.00 target after recent downgrades and target reductions from some firms.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) CIO Mitchell Young Williams sold 263,863 shares of Biosig Technologies stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $0.79, for a total value of $208,451.77. Following the completion of the sale, the executive directly owned 3,037,648 shares of the company's stock, valued at approximately $2,399,741.92. This trade represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Biosig Technologies Trading Down 14.0%
Shares of STEX opened at $1.02 on Tuesday. The business has a 50-day moving average price of $1.49. Biosig Technologies, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $14.11. The stock has a market cap of $183.86 million, a price-to-earnings ratio of -0.11 and a beta of 1.58.
Biosig Technologies (NASDAQ:STEX - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($8.23) earnings per share for the quarter.
Analysts Set New Price Targets
STEX has been the subject of several analyst reports. Wall Street Zen downgraded Biosig Technologies from a "hold" rating to a "strong sell" rating in a research note on Sunday, April 5th. Needham & Company LLC reduced their target price on Biosig Technologies from $12.00 to $9.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Finally, Weiss Ratings raised Biosig Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Biosig Technologies presently has a consensus rating of "Hold" and a consensus target price of $9.00.
Get Our Latest Research Report on STEX
Biosig Technologies Company Profile
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
